The listing of claims presented below replaces all prior versions, and listings, of claims in the application.

RECEIVED CENTRAL FAX CENTER NOV 2 1 2006

Listing of claims

Claims 1-67 (cancel)

- 68. (new) A pharmaceutical composition for the treatment of an anorectal or colonic disease or condition comprising from 0.1% to 99% by weight of an extract of the plant *Euphorbia prostrata* said extract containing flavonoids and phenolic compounds, wherein the flavonoids are apigenin-7-glycoside; luteolin-7-glycoside; apigenin; luteolin; and quercetin; wherein apigenin-7-glycoside is about 1-4% by weight of the extract; luteolin-7-glycoside is about 0.3-2% by weight of the extract; apigenin is about 0.001-0.3% by weight of the extract; luteolin is about 0.001-0.3% by weight of the extract; and wherein the phenolic compounds are ellagic acid, gallic acid, and tannins; wherein the ellagic acid is about 1-15% by weight of the extract; gallic acid is about 1-12% by weight of the extract and tannins are about 1-10% by weight of the extract; said composition optionally comprising one or more additional therapeutic agents.
- 69. (new) The composition according to claim 68 wherein the anorectal or colonic disease or condition is a hemorrhoid, fissure, crack, fistula, abscess or inflammatory bowel disease
- 70. (new) The pharmaceutical composition as claimed in claim 68, wherein the extract comprises about 2.5–3.5% by weight of apigenin-7-glycoside; 0.5–1.5% by weight of luteolin-7-glycoside; 0.05–0.2% by weight of apigenin; 0.05–0.2% by weight of luteolin,; 0.05–0.2% by weight of quercetin; 4–15% by weight of ellagic acid,; 4–12% by weight of gallic acid; and about 3-8% by weight of tannins.
- 71. (new) The pharmaceutical composition as claimed in claim 68, wherein the composition further comprises one or more pharmaceutically acceptable carriers, pharmaceutically acceptable bases or combinations thereof.

- 72. (new). The pharmaceutical composition as claimed in claim 68 further comprising one or more therapeutic agents selected from astringents, anesthetics, vasoconstrictors, protectants, counterirritants, keratolytics, anti-cholinergics, wound healing agents and anti-microbial agents.
- 73. (new)The pharmaceutical composition as claimed in claim 72, wherein the astringent is selected from the group consisting on calamine, zinc oxide, hamamelis water, bismuthresorcinol compound, bismuth subgallate, Peruvian balsam, aluminium chlorohydroxy allantoinate, and tannic acid or in a combination thereof.
- 74. (new) The pharmaceutical composition as claimed in claim 72, wherein the anesthetic is selected from the group consisting of benzocaine, diperodon, pramoxine, camphor, dibucaine, phenol, tetracaine, and phenacaine or a combination thereof.
- 75. (new) The pharmaceutical composition as claimed in claim 72, wherein the protectant is selected from the group consisting of aluminium hydroxide gel, calamine, cocoa butter, cod or shark liver oil, starch, white petroleum, wool alcohol, zinc oxide, vegetable or castor oil, polyethylene glycol, and propylene glycol or a combination thereof,
- 76. (new) The pharmaceutical composition as claimed in claim 72, wherein the wound healing agent is selected from the group consisting of vitamin A, vitamin D, Peruvian balsam, and cod liver oil or a combination thereof.
- 77. (new) The pharmaceutical composition as claimed in claim 72, wherein the keratolytic is selected from the group consisting of aluminium chlorohydroxy allantoinate and resorcinol, or a combination thereof.
- 78. (new) The pharmaceutical composition as claimed in claim 68, wherein the composition is in the form of a cream, ointment, solution, spray, foam, suppository, medicated pad, bandage, powder, suspension, film, flake, oral hard gelatin capsule, soft gelatin capsule, coated tablet, uncoated tablet, modified release dosage form, liquid, lozenge, buccal or sublingual dosage form, wafer, caplet, or parenteral dosage form to be infiltered at the site of the injection.

- 79. (new). A process for preparing a pharmaceutical composition for the treatment of anorectal or colonic disease comprising of an extract of the plant Euphorbia prostrata containing flavonoids and phenolic compounds, wherein the flavonoids are apigenin-7-glycoside; luteolin-7-glycoside; apigenin; luteolin; and quercetin; wherein apigenin-7-glycoside is about 1-4% by weight of the extract; luteolin-7-glycoside is about 0.3-2% by weight of the extract; apigenin is about 0.001-0.3% by weight of the extract; luteolin is about 0.001-0.3% by weight of the extract; and quercetin is about 0.001-0.3% by weight of the extract; and quercetin is about 0.001-0.3% by weight of the extract; and wherein the phenolic compounds are ellagic acid, gallic acid, and tannins; wherein the ellagic acid is about 1-15% by weight of the extract; gallic acid is about 1-12% by weight of the extract and tannins are about 1-10% by weight of the extract by weight, with one or more pharmaceutically acceptable carriers and bases and, optionally with one or more additional therapeutic agents, comprising the steps of:
- a) drying the plant Euphorbia prostrata,
- b) making a powder from the dried plant,
- c) extracting the dry course powder with a polar solvent repetitively to obtain an extract,
- d) distilling the extract to obtain a concentrated extract,
- e) washing the concentrated extract with a non-polar organic solvent,
- f) optionally re-extracting the washed polar extract in a medium polarity organic solvent, distilling the extract followed by dehydrating the extract, and
- g) drying the extract and optionally adding one or more pharmaceutically acceptable carriers, bases or a combination thereof.

- 80. (new) A method of treatment of anorectal or colonic disease or condition comprising administering a pharmaceutical composition according to claim 68 to a patient in need thereof.
 - 81. (new) A method of treatment as claimed in claim 80, wherein the anorectal or colonic disease or condition is a hemorrhoid, fissure, crack, fistula, abscess or inflammatory bowel disease.